GYG2

GYG2 (glycogenin-2) is a self-glucosylating protein originally characterized as an initiator of glycogen biosynthesis, expressed preferentially in liver, heart, and pancreas, with multiple isoforms arising from alternative splicing (PMID:9346895). In vitro it autoglucosylates and the resulting product serves as a primer that is elongated by glycogen synthase (PMID:9346895). The gene maps to Xp22.3, is subject to X chromosome inactivation, and appears to be primate-specific, with no functional ortholog in rodents (PMID:10721716, PMID:11463169, PMID:19684479). More recent structural and biochemical work revises the simple initiator model: GYG2 exhibits minimal autoglycosylation activity relative to GYG1 and acts as a suppressor of glycogen formation, coordinating with GYG1 to modulate glycogen synthase activity and glycogen assembly in a cell-type-dependent manner to maintain cellular glucose homeostasis (PMID:40670355). Consistent with a functional redundancy with GYG1, complete GYG2 deletion in hemizygous human males does not impair liver glycogen synthesis, as GYG1 compensates (PMID:25751106). A hemizygous missense mutation (p.W222S) abolishes GYG2 self-glucosylation activity in vitro and destabilizes the protein, and was identified in male siblings with Leigh syndrome (PMID:24100632). In glioma cells, GYG2 has a separable anti-apoptotic, pro-survival role: its downregulation upon oncolytic VSV-M51 infection promotes tumor cell apoptosis (PMID:41350820).

1. 1997 High

   Established that GYG2 is an enzymatically active self-glucosylating protein capable of initiating glycogen synthesis, defining its core biochemical activity and tissue distribution.

   Evidence Expression in E. coli and COS cells with in vitro self-glucosylation and glycogen synthase elongation assays; fractionation in H4IIEC3 hepatoma cells

   PMID:9346895

   Open questions at the time

   • Did not establish physiological contribution relative to GYG1
   • Functional role of distinct splice isoforms unresolved
2. 2000 High

   Defined the genomic structure and X-linked chromosomal location of GYG2, placing it in an X-Y shared gene region at Xp22.3.

   Evidence Genomic cloning, exon structure analysis, and FISH/STS mapping

   PMID:10721716

   Open questions at the time

   • Functional consequence of X-Y shared context not addressed
   • Y-chromosome remnant activity not tested
3. 2001 Medium

   Indicated GYG2 is primate-specific with no rodent ortholog, implying species differences in glycogen initiation regulation.

   Evidence Sequence database searches and failed generation of rodent-reactive reagents (negative result)

   PMID:11463169

   Open questions at the time

   • Negative finding limited by database completeness at the time
   • Does not explain functional consequence of primate-specificity
4. 2009 Medium

   Determined that GYG2 undergoes X chromosome inactivation in normal fibroblasts, correcting prior hybrid-cell reports of XCI escape.

   Evidence Allele-specific expression analysis in skewed-XCI fibroblasts and 5' DNA methylation profiling

   PMID:19684479

   Open questions at the time

   • Tissue-specificity of XCI status not assessed
   • Dosage consequences for glycogen metabolism unexplored
5. 2013 High

   Linked a specific missense mutation to loss of GYG2 catalytic activity and a human neurodegenerative phenotype.

   Evidence Whole exome sequencing of Leigh syndrome siblings, in vitro self-glucosylation assay of WT vs. p.W222S mutant, and structural modeling

   PMID:24100632

   Open questions at the time

   • Causal link between GYG2 loss and Leigh syndrome not proven by rescue or animal model
   • Single family
6. 2015 High

   Showed GYG2 is dispensable for liver glycogen synthesis in humans, demonstrating GYG1 compensation in vivo.

   Evidence CNV-identified 102-kb GYG2 deletion carriers analyzed by glucagon stimulation tests, liver biopsy EM, and RT-PCR for GYG1/GYG2

   PMID:25751106

   Open questions at the time

   • Does not address GYG2 function in heart or pancreas
   • Compensation mechanism beyond GYG1 presence not dissected
7. 2019 Medium

   Characterized the genomic deletion context of GYG2 within the XG-region Xgnull phenotype, clarifying its chromosomal neighborhood.

   Evidence Exon sequencing, deletion-specific PCR, and Sanger sequencing of recombination junctions

   PMID:30938838

   Open questions at the time

   • Metabolic consequence of the GYG2-spanning deletion not assessed
   • Single lab
8. 2025 High

   Revised the functional model: GYG2 has minimal autoglycosylation and acts as a suppressor rather than initiator of glycogen formation, coordinating with GYG1 to regulate glycogen synthase and glucose homeostasis.

   Evidence Structural biology, biochemical autoglycosylation assays comparing GYG1 and GYG2, and cellular models

   PMID:40670355

   Open questions at the time

   • Molecular basis of suppression versus initiation not fully mapped
   • Cell-type determinants of coordination with GYG1 unresolved
9. 2025 Medium

   Identified a context-specific anti-apoptotic role for GYG2 in glioma, separable from its glycogen-metabolic function.

   Evidence siRNA knockdown/overexpression with rescue, qRT-PCR, apoptosis assays in VSV-M51-infected glioma cells, and tumor dataset analysis

   PMID:41350820

   Open questions at the time

   • Molecular pathway linking GYG2 to apoptosis suppression not defined
   • Single lab; in vivo tumor relevance untested

• How GYG2's suppressor activity and its catalytic/structural features mechanistically reconcile with its earlier-described initiator activity and its anti-apoptotic role in cancer remains unresolved.
• No unified mechanism connecting glycogen suppression to apoptosis regulation
• Tissue-specific physiological role in heart and pancreas uncharacterized
• No structural explanation for switch between initiation and suppression